MAP
UPB

Moody Aldrich Partners’s Upstream Bio Inc UPB Stock Holding History

Moody Aldrich Partners’s Portfolio UPB Stock Details UPB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-74,773
Closed -$1.23M – 219
2024
Q4 		$1.23M Buy
+74,773
New +$1.67M 0.23% 110

Other funds holding UPB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Moody Aldrich Partners's UPB Position: Q1 2025 in Review

Moody Aldrich Partners sold out of Upstream Bio Inc (UPB) in Q1 2025, closing a stake of 74,773 shares — an estimated $1.23M sold.

Moody Aldrich Partners first reported a position in UPB in Q4 2024 and held it in 1 quarter. The position peaked at $1.23M in Q4 2024. 79 funds tracked by Wall St. Rank hold UPB as of Q1 2025.

  • Moody Aldrich Partners reported no remaining Upstream Bio Inc position as of Q1 2025 after selling out during the quarter.
  • Moody Aldrich Partners sold 74,773 Upstream Bio Inc shares in Q1 2025, an estimated $1.23M.
  • Moody Aldrich Partners first reported a position in Upstream Bio Inc in Q4 2024 and held it in 1 quarter.
  • Moody Aldrich Partners's Upstream Bio Inc position peaked at $1.23M in Q4 2024.
  • 79 funds tracked by Wall St. Rank held Upstream Bio Inc as of Q1 2025.

Based on Moody Aldrich Partners's 13F filing for Q1 2025, filed 29 Apr 2025.